Holen Sie sich die Stockscreener-App
24.73
4.85%
1.1319
Schlusskurs vom Vortag:
$23.60
Offen:
$24.69
24-Stunden-Volumen:
1.32M
Relative Volume:
0.50
Marktkapitalisierung:
$3.96B
Einnahmen:
$295.41M
Nettoeinkommen (Verlust:
$-49.64M
KGV:
-75.54
EPS:
-0.3274
Netto-Cashflow:
$-29.54M
1W Leistung:
+9.64%
1M Leistung:
+18.85%
6M Leistung:
+56.91%
1J Leistung:
+97.33%
1-Tages-Spanne:
$24.28
$24.95
1-Wochen-Bereich:
$21.83
$24.96
52-Wochen-Spanne:
$11.85
$24.96
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
24.72 | 3.61B | 295.41M | -49.64M | -29.54M | -0.3274 |
TMO
Thermo Fisher Scientific Inc
|
586.95 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.78 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
588.64 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
321.32 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
144.78 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
ADPT|Adaptive Biotechnologies Corp|Price:22.540|Chg%:+0.270 - TradingKey
Adaptive Biotechnologies Corp (ADPT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Adaptive Biotechnologies Corp (ADPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Adaptive Biotechnologies Corp (ADPT) Balance Sheet - TradingKey
Adaptive Biotechnologies Corp (ADPT) Cash Flow - TradingKey
Adaptive Biotechnologies Corp (ADPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Adaptive Biotechnologies Corp - TradingKey
Adaptive Biotechnologies Corp (ADPT) Institutional Confidence - TradingKey
Adaptive Biotechnologies Corp (ADPT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Adaptive Biotechnologies Corp (ADPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Adaptive Biotechnologies Corp (ADPT) Income Statement - TradingKey
ADPT|Adaptive Biotechnologies Corp|Price:22.270|Chg%:-0.040 - TradingKey
Adaptive Biotechnologies Corp. Revenue Breakdown – HAM:1HM - TradingView
Adaptive Biotechnologies (ADPT) After Loss Forecasts Improve Is The Rally Already Priced In - Yahoo Finance
Adaptive Biotechnologies (ADPT) Stock May Be 22% Undervalued As Growth Hopes Build - Yahoo Finance
Form 4 Adaptive Biotechnologies Corp For: 23 July - Investing.com India
Adaptive Biotechnologies Corp (ADPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 4 Adaptive Biotechnologies Corp For: 23 July By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CSO Harlan Robins sells $10.78m in stock - Investing.com
Adaptive Biotechnologies CSO Harlan Robins sells $10.78m in stock By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies Corp (ADPT) CSO exercises options and sells 492,400 shares - Stock Titan
ADPT: Adaptive Biotechnologies Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Will Earnings Estimate Upgrades and a Smaller Projected Loss Change Adaptive Biotechnologies' (ADPT) Narrative? - Yahoo Finance Singapore
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
ADPT (ADPT) Form 144 shows Harlan Robins planning sizable stock sale - Stock Titan
Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Revenue Growth Amidst Valuation Challenges - DirectorsTalk Interviews
Form 4 Adaptive Biotechnologies Corp For: 21 July By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells 5,000 shares in plan - Stock Titan
Form 4 Adaptive Biotechnologies Corp For: 17 July By Investing.com - Investing.com Canada
Adaptive Biotechnologies CPO Lo reports $2.39m stock sale - Investing.com
Adaptive Biotechnologies CPO Lo reports $2.39m stock sale By Investing.com - Investing.com India
Adaptive Biotechnologies Corp (ADPT) officer exercises 105,762 options and sells 105,762 shares - Stock Titan
Calendrier des fractionnements d'actions pour: - Yahoo Finance France
Planned 5,000-share stock sale for ADPT (NASDAQ: ADPT) - Stock Titan
Adaptive Biotechnologies stock hits 52-week high at 22.81 USD - Investing.com UK
Adaptive Biotechnologies stock hits 52-week high at 22.81 USD By Investing.com - Investing.com Canada
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run - Yahoo Finance
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run - The Motley Fool
Adaptive Biotechnologies to report Q2 2026 results on July 29 - scanx.trade
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026 - The Manila Times
ADPT Maintained by Morgan Stanley -- Price Target Raised to $20. - GuruFocus
Adaptive biotechnologies CSO Harlan Robins sells $8.5m in stock By Investing.com - Investing.com Nigeria
Adaptive biotechnologies CSO Harlan Robins sells $8.5m in stock - Investing.com
Form 4 Adaptive Biotechnologies Corp For: 7 July By Investing.com - Investing.com South Africa
CSO sells 386,240 Adaptive Biotechnologies (NASDAQ: ADPT) shares under plan - Stock Titan
Enterprise value to EBIT forward of Adaptive Biotechnologies Corp. – DUS:1HM - TradingView
Adaptive Biotechnologies CPO Francis Lo sells $2.16m in stock By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies CPO Francis Lo sells $2.16m in stock - Investing.com
Adaptive Biotechnologies CCO Susan Bobulsky sells $10,714 in stock - Investing.com
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):